|Day Low/High||77.69 / 80.00|
|52 Wk Low/High||56.81 / 80.49|
Stocks finish week sharply lower on worries over global economic growth slowing after earlier surging on Fed's more accommodating stance.
We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.
As much as we continue to believe in the company and its strong organic growth trends, discipline calls for us to lock in some of our big gains.
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.
- Alinity m will allow labs to meet the growing demand for infectious disease testing by offering increased efficiency and market-leading speed and accuracy
- New MOMENTUM 3 data show the best outcomes seen in a randomized controlled clinical trial for left ventricular assist device (LVAD) therapy
- New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy
- The world's first minimally invasive mitral valve repair device now approved to help difficult-to-treat heart failure patients with clinically significant secondary mitral regurgitation
With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #66 spot from Synopsys Inc , according to ETF Channel. Below is a chart of Abbott Laboratories versus Synopsys Inc plotting their respective rank within the S&P 500 over time (ABT plotted in blue; SNPS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
- Five late-breaking data presentations at ACC 2019 showcase the breadth and depth of Abbott's cardiovascular portfolio
Regional Medical Laboratory, Inc., which is part of the Ascension network, partners with Abbott, the global health leader, to advance lab capabilities and help improve health outcomes
Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.
We made several trades this week as markets edged higher on optimism over a U.S.-China trade deal.
- Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control
Collaboration will enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products
- New point-of-care rapid test identifies and helps make effective care more accessible for millions of people living with hepatitis B, in support of World Health Organization (WHO) hepatitis targets
As the U.S. and the world grow fatter, some investors are seeing green as they bulk up on stocks of companies on the front-lines of this 21st century Battle of the Bulge.
These mobile investment apps can get you up and trading fast, sometimes with no trading fees.
ABT is pointed up after trading in a choppy range since October.
Jim Cramer takes a closer look at Caterpillar, PG&E, Nio, Visa, Tenneco and more.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.